Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors

被引:100
作者
Kwekkeboom, Dik J. [1 ]
Krenning, Eric P. [1 ]
机构
[1] Univ Med Ctr, Erasmus MC, Dept Nucl Med, NL-3015 CE Rotterdam, Netherlands
关键词
Neuroendocrine tumor; Carcinoid; Radionuclide therapy; PRRT; Treatment; RADIOLABELED SOMATOSTATIN ANALOG; PHASE-I; RADIOPEPTIDE LU-177-OCTREOTATE; CARCINOID-SYNDROME; SALVAGE THERAPY; COMBINATION; TOXICITY; SURVIVAL; Y-90-DOTATOC; CAPECITABINE;
D O I
10.1016/j.hoc.2015.09.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors patients. Most studies report objective response rates in 15% to 35% of patients. Progression-free (PFS) and overall survival (OS) compare favorably with that for somatostatin analogues, chemotherapy, or newer, "targeted" therapies. Prospective, randomized data regarding the potential PFS and OS benefit of PRRT compared with standard therapies is anticipated.
引用
收藏
页码:179 / +
页数:15
相关论文
共 53 条
  • [51] Yang F, 2014, NEW ENGL J MED, V371, P1556, DOI [10.1056/NEJMoa1316158, 10.1056/NEJMc1409757]
  • [52] Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
    Yao, James C.
    Shah, Manisha H.
    Ito, Tetsuhide
    Bohas, Catherine Lombard
    Wolin, Edward M.
    Van Cutsem, Eric
    Hobday, Timothy J.
    Okusaka, Takuji
    Capdevila, Jaume
    de Vries, Elisabeth G. E.
    Tomassetti, Paola
    Pavel, Marianne E.
    Hoosen, Sakina
    Haas, Tomas
    Lincy, Jeremie
    Lebwohl, David
    Oberg, Kjell
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06) : 514 - 523
  • [53] Clinical experience with α-particle-emitting 211At:: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    Zalutsky, Michael R.
    Reardon, David A.
    Akabani, Gamal
    Coleman, Edward
    Friedman, Allan H.
    Friedman, Henry S.
    McLendon, Roger E.
    Wong, Terence Z.
    Bigner, Darell D.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (01) : 30 - 38